VERV News and Press, Verve Therapeutics Inc.

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...

2024-06-27 10:17:45 ET Information Technology has been the best performing name among all 11 S&P 500 ( SP500 ) sectors in the first half of 2024, but Cathie Wood’s actively managed ARK Innovation ETF ( NYSEARCA: ARKK ) - which aims to provide investors exposure to dis...

2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-13 06:44:46 ET Summary Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD. VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk. Verve's leading programs, V...

2024-05-31 07:08:01 ET More on Verve Therapeutics Verve Therapeutics: An Update On Human CRISPR Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause Verve Therapeutics gains as COO buys shares Read the full article on Seeking Alpha ...

Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approac...

2024-05-24 21:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-16 11:20:41 ET More on Verve Therapeutics Verve Therapeutics: An Update On Human CRISPR Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause MGNI, VERV and GWAV among pre-market gainers Verve drops after pausing trial enrollments f...

2024-05-16 09:25:25 ET More on pre-market movers Magnite, Inc. (MGNI) Q1 2024 Earnings Call Transcript Magnite, Inc. 2024 Q1 - Results - Earnings Call Presentation Magnite: Impact From The Disney Deal Is Not As Bad As It Sounds Magnite Non-GAAP EPS of $0.05 b...

2024-05-14 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...